clinical trial · NCT06965569
Multiple Ascending Dose Phase 1 Study of ALA-3000
Treatment Resistant DepressionALA-3000Placeboescitalopram, sertraline, duloxetine or venlafaxine XR
brief summary
This is a randomized, double-blind, placebo-controlled, multiple-dose study of ALA-3000 designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy in subjects with treatment-resistant depression (TRD).
started
Apr 21, 2025
primary completion
Dec 30, 2025
completion
Dec 30, 2025
last updated
Dec 31, 2025
official title
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study of ALA-3000, Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Subjects With Treatment-Resistant Depression (TRD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol